JP2003500022A - トリボネクチン - Google Patents

トリボネクチン

Info

Publication number
JP2003500022A
JP2003500022A JP2000614279A JP2000614279A JP2003500022A JP 2003500022 A JP2003500022 A JP 2003500022A JP 2000614279 A JP2000614279 A JP 2000614279A JP 2000614279 A JP2000614279 A JP 2000614279A JP 2003500022 A JP2003500022 A JP 2003500022A
Authority
JP
Japan
Prior art keywords
tribonectin
seq
amino acid
acid sequence
msf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000614279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500022A5 (fr
Inventor
グレゴリー ディー． ジェイ，
Original Assignee
ロード アイランド ホスピタル， ア ライフスパン パートナー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23152784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003500022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ロード アイランド ホスピタル， ア ライフスパン パートナー filed Critical ロード アイランド ホスピタル， ア ライフスパン パートナー
Publication of JP2003500022A publication Critical patent/JP2003500022A/ja
Publication of JP2003500022A5 publication Critical patent/JP2003500022A5/ja
Priority to US14/167,489 priority Critical patent/US20140179611A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Conductive Materials (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Insulating Materials (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
JP2000614279A 1999-04-23 2000-04-24 トリボネクチン Withdrawn JP2003500022A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/167,489 US20140179611A1 (en) 1999-04-23 2014-01-29 Tribonectins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/298,970 1999-04-23
US09/298,970 US6743774B1 (en) 1999-04-23 1999-04-23 Tribonectins
PCT/US2000/010953 WO2000064930A2 (fr) 1999-04-23 2000-04-24 Tribonectines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011234344A Division JP2012070738A (ja) 1999-04-23 2011-10-25 トリボネクチン

Publications (2)

Publication Number Publication Date
JP2003500022A true JP2003500022A (ja) 2003-01-07
JP2003500022A5 JP2003500022A5 (fr) 2007-06-28

Family

ID=23152784

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000614279A Withdrawn JP2003500022A (ja) 1999-04-23 2000-04-24 トリボネクチン
JP2011234344A Withdrawn JP2012070738A (ja) 1999-04-23 2011-10-25 トリボネクチン
JP2014096656A Pending JP2014144015A (ja) 1999-04-23 2014-05-08 トリボネクチン
JP2015256079A Expired - Lifetime JP5909592B2 (ja) 1999-04-23 2015-12-28 トリボネクチン
JP2016099618A Withdrawn JP2016172760A (ja) 1999-04-23 2016-05-18 トリボネクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011234344A Withdrawn JP2012070738A (ja) 1999-04-23 2011-10-25 トリボネクチン
JP2014096656A Pending JP2014144015A (ja) 1999-04-23 2014-05-08 トリボネクチン
JP2015256079A Expired - Lifetime JP5909592B2 (ja) 1999-04-23 2015-12-28 トリボネクチン
JP2016099618A Withdrawn JP2016172760A (ja) 1999-04-23 2016-05-18 トリボネクチン

Country Status (9)

Country Link
US (6) US6743774B1 (fr)
EP (1) EP1173567B2 (fr)
JP (5) JP2003500022A (fr)
AT (1) ATE425253T1 (fr)
AU (1) AU781564B2 (fr)
CA (1) CA2367750C (fr)
DE (1) DE60041761D1 (fr)
ES (1) ES2324199T5 (fr)
WO (1) WO2000064930A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502122A (ja) * 2003-08-14 2007-02-08 ワイス 組換えルブリシン分子およびその使用
WO2010087521A1 (fr) * 2009-01-29 2010-08-05 独立行政法人理化学研究所 Préparation combinée pour traiter les maladies articulaires
JP2012527485A (ja) * 2009-05-22 2012-11-08 ルブリス，エルエルシー． Ｐｒｇ４及びその治療調節作用の応用及び使用
JP2016535590A (ja) * 2013-10-22 2016-11-17 ルブリス，エルエルシー． 組換えラブリシンの産生
JP2022058602A (ja) * 2016-01-13 2022-04-12 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 哺乳動物の変形性関節症及び関連する関節症状の治療に有用なｈａｓ２及びルブリシンを含む骨保護遺伝子を発現する組換えａａｖベクター

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
EP1255781A1 (fr) * 2000-02-09 2002-11-13 Glaxo Group Limited Proteines de zone superficielle liees a un anticorps et leurs utilisations dans le cadre de procedes de filtrage et de diagnostic
GB0003092D0 (en) 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
US20030180948A1 (en) * 2000-12-29 2003-09-25 Hutchins Jeff T. Superficial zone protein and methods of making and using same
WO2002102403A1 (fr) * 2001-06-14 2002-12-27 Novo Nordisk A/S Reparation des muqueuses par des peptides dimeres tff
WO2005000331A2 (fr) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Methodes et compositions permettant de traiter et de prevenir des troubles degeneratifs des articulations
US20090155200A1 (en) * 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
EP1778360A2 (fr) * 2004-07-23 2007-05-02 Mucosal Therapeutics LLC Compositions et procedes de viscosupplementation
EP1827478A4 (fr) * 2004-12-03 2009-08-05 Mucosal Therapeutics Llc Methodes de traitement d'articulations lesees ou malades
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
JP5362554B2 (ja) * 2006-05-17 2013-12-11 ストライカー コーポレイション 軟骨の欠損を処置するための可溶性形態形成タンパク質の使用
US20090068247A1 (en) * 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
PT2285364E (pt) * 2008-05-07 2015-02-24 Univ California Reposição e enriquecimento terapêutico de lubrificação da superficie ocular
US8980840B2 (en) 2009-01-13 2015-03-17 Schepens Eye Research Institute Therapeutic modulation of vaginal epithelium boundary lubrication
US11213566B2 (en) 2010-01-19 2022-01-04 Lubris Llc Oral care compositions and methods
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
US20130116186A1 (en) * 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
EP2948553B1 (fr) 2013-01-25 2020-04-01 Baylor College Of Medicine Système d'administration et d'expression d'une thérapie génique adénovirale dépendante d'un virus auxiliaire
EP3074022B1 (fr) 2013-11-26 2022-03-30 Lubris LLC Compositions et procédés pour inhiber les interactions intercellulaires
SG11201705636SA (en) 2015-01-26 2017-08-30 Lubris Llc Use of prg4 as an anti-inflammatory agent
LT3300482T (lt) 2015-05-19 2021-10-25 Lubris Llc Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui
WO2017144563A1 (fr) 2016-02-23 2017-08-31 Lynxon Ab Procédé de diagnostic de l'arthrite ou d'une autre maladie dégradant les articulations
US20230127949A1 (en) 2020-02-24 2023-04-27 Novartis Ag Purification of recombinantly produced polypeptides
JP7063369B2 (ja) * 2020-12-07 2022-05-09 株式会社三洋物産 遊技機
WO2023212598A1 (fr) 2022-04-27 2023-11-02 Lubris Llc Procédés de fabrication de films polymères

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505631A (ja) * 1991-01-18 1994-06-30 ジェネティックス・インスティテュート・インコーポレイテッド 巨核球刺激因子

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734862A (en) 1956-02-14 Synthetic casein fiber elastic grease
US2487377A (en) 1948-04-17 1949-11-08 Socony Vacuum Oil Co Inc Lubricant
US2878184A (en) 1953-12-29 1959-03-17 Rockwell Mfg Co Hydrocarbon resistant glycerol base lubricant
AR207237A1 (es) 1974-02-25 1976-09-22 Thomas A Procedimiento para obtener extractos biologicos estables liofilizados solubles constituidos por complejos proteicos termorresistentes
WO1981002977A1 (fr) 1980-04-25 1981-10-29 Orthana Kemisk Fab As Solutions sterilisees, preservees, stables, et contenant de la mucine et procede de sterilisation
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
GB8803697D0 (en) 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5260417A (en) 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
AU652022B2 (en) 1991-02-12 1994-08-11 C.R. Bard Inc. Injectable medical device
JPH04278061A (ja) 1991-03-05 1992-10-02 Suntory Ltd 栄養食品
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5515590A (en) 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5709020A (en) 1994-07-19 1998-01-20 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5510122A (en) 1994-09-28 1996-04-23 The Research Foundation Of State University Of New York Preparation and use of whole saliva
FR2726188B1 (fr) * 1994-11-02 1996-12-20 Inst Vaisseaux Et Du Sang Composition glycosaminoglycane/facteur de croissance megacaryocytaire, utilisation en therapeutique
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
AT405477B (de) * 1996-04-03 1999-08-25 Norbert Mag Fuchs Kombinationspräparat
CA2270223A1 (fr) 1996-10-28 1998-05-07 Carson B. Burgstiner (Deceased) Procedes et compositions pour la complementation alimentaire
US6960562B2 (en) * 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7001881B1 (en) * 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
JP2004517030A (ja) * 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド グリコシルトランスフェラーゼインヒビター
WO2001007068A1 (fr) 1999-07-23 2001-02-01 Case Western Reserve University Nouveaux procedes et reactifs destines au traitement de l'arthrose
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
GB0003092D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
US20030180948A1 (en) * 2000-12-29 2003-09-25 Hutchins Jeff T. Superficial zone protein and methods of making and using same
JP2005508297A (ja) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｐ２ｙプリン受容体作用物質による関節潤滑
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
US7642236B2 (en) 2003-08-14 2010-01-05 Wyeth Recombinant lubricin molecules and uses thereof
US20070275032A1 (en) 2004-03-05 2007-11-29 Synthes (U.S.A.) Use Of A Mixture For The Production Of An Agent For Treating Defective Or Degenerated Cartilage In The Production Of Natural Cartilage Replacement In Vitro
EP1778360A2 (fr) * 2004-07-23 2007-05-02 Mucosal Therapeutics LLC Compositions et procedes de viscosupplementation
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505631A (ja) * 1991-01-18 1994-06-30 ジェネティックス・インスティテュート・インコーポレイテッド 巨核球刺激因子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5002007525; Ｊ．Ｏｒｔｈｏｐ．　Ｒｅｓ． Ｖｏｌ．１７，　Ｎｏ．１, 199901, Ｐ．１１０-１２０ *
JPN5002007526; Ｊ．　Ｂｉｏｍｅｄ．　Ｍａｔｅｒ．　Ｒｅｓ． Ｖｏｌ．４０，　Ｎｏ．３, 1998, Ｐ．４１４-４１８ *
JPN6010012687; Ｂｉｏｃｈｅｍ．　Ｂｉｏｐｈｙｓ．　Ｒｅｓ．　Ｃｏｍｍｕｎ． Ｖｏｌ．２５４, 199901, Ｐ．５３５-５４１ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502122A (ja) * 2003-08-14 2007-02-08 ワイス 組換えルブリシン分子およびその使用
WO2010087521A1 (fr) * 2009-01-29 2010-08-05 独立行政法人理化学研究所 Préparation combinée pour traiter les maladies articulaires
JP5629940B2 (ja) * 2009-01-29 2014-11-26 独立行政法人理化学研究所 関節疾患治療用の組み合わせ製剤
US9095551B2 (en) 2009-01-29 2015-08-04 Riken Combined preparation for treating joint diseases
JP2012527485A (ja) * 2009-05-22 2012-11-08 ルブリス，エルエルシー． Ｐｒｇ４及びその治療調節作用の応用及び使用
JP2016535590A (ja) * 2013-10-22 2016-11-17 ルブリス，エルエルシー． 組換えラブリシンの産生
JP2020039348A (ja) * 2013-10-22 2020-03-19 ルブリス，エルエルシー． 組換えラブリシンの産生
JP2022058602A (ja) * 2016-01-13 2022-04-12 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 哺乳動物の変形性関節症及び関連する関節症状の治療に有用なｈａｓ２及びルブリシンを含む骨保護遺伝子を発現する組換えａａｖベクター
US11905531B2 (en) 2016-01-13 2024-02-20 Genzyme Corporation Recombinant AAV vectors expressing osteoprotective genes, including HAS2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals

Also Published As

Publication number Publication date
US6743774B1 (en) 2004-06-01
CA2367750A1 (fr) 2000-11-02
US7618941B2 (en) 2009-11-17
JP2012070738A (ja) 2012-04-12
CA2367750C (fr) 2013-10-22
EP1173567A2 (fr) 2002-01-23
US8680057B2 (en) 2014-03-25
US20140179611A1 (en) 2014-06-26
AU781564B2 (en) 2005-06-02
JP2016172760A (ja) 2016-09-29
EP1173567B2 (fr) 2012-10-31
ATE425253T1 (de) 2009-03-15
ES2324199T3 (es) 2009-08-03
US20100204087A1 (en) 2010-08-12
DE60041761D1 (de) 2009-04-23
JP2016041769A (ja) 2016-03-31
WO2000064930A2 (fr) 2000-11-02
WO2000064930A3 (fr) 2001-01-25
JP5909592B2 (ja) 2016-04-26
ES2324199T5 (es) 2013-03-20
AU4485200A (en) 2000-11-10
US20130072435A1 (en) 2013-03-21
JP2014144015A (ja) 2014-08-14
EP1173567B1 (fr) 2009-03-11
US8026346B2 (en) 2011-09-27
US20040229804A1 (en) 2004-11-18
US20100048458A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
JP5909592B2 (ja) トリボネクチン
US6960562B2 (en) Tribonectin polypeptides and uses thereof
AU670770B2 (en) Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
US7001881B1 (en) Tribonectins
US7741055B2 (en) Prostatic growth factor
EP0823478A2 (fr) Gène humaine du cartilage, du type 9p 39
PT94754B (pt) Processo de obtencao de inibidor de factor de necrose tumoral e de isolamento de genes que codificam o referido inibidor
EP1663291B1 (fr) Molécules de lubricine recombinantes et leurs utilisations
WO1996018730A1 (fr) Facteur de croissance prostatique
US20030180948A1 (en) Superficial zone protein and methods of making and using same
JP4255986B2 (ja) 消化管潰瘍のモルフォゲン治療
JP2003513631A (ja) 新規ポリペプチドホルモンフォスファトニン
JPWO2008013082A1 (ja) ガレクチン９−ポリマーコンジュゲート
US20030158115A1 (en) Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US6043216A (en) Methods and composition for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US20060142199A1 (en) CD-44 like protein
AU2079900A (en) Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140708

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140910

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140912